Evidence map›Paper›PMID 41908235›Full record

ReviewProstate international2026

Advances in focal therapy for prostate cancer: current modalities, outcomes, and future directions.

Rocio Roldan-Testillano, Lara Rodriguez-Sanchez, Claudia Covarrubias, Francisco Durazo-Ruiz, Adel Arezki, Maurice Anidjar, Rafael Sanchez-Salas

Abstract readReview
In one paragraph

Review in Prostate international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rocio Roldan-TestillanoDepartment of Urology, McGill University Health Centre, Montréal, Canada.
Lara Rodriguez-SanchezDepartment of Urology, Institut Mutualiste Montsouris, Paris, France.
Claudia CovarrubiasDepartment of Urology, McGill University Health Centre, Montréal, Canada.
Francisco Durazo-RuizDepartment of Urology, McGill University Health Centre, Montréal, Canada.
Adel ArezkiDepartment of Urology, McGill University Health Centre, Montréal, Canada.
Maurice AnidjarDepartment of Urology, McGill University Health Centre, Montréal, Canada.
Rafael Sanchez-SalasDepartment of Urology, McGill University Health Centre, Montréal, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Focal therapy (FT) has emerged as a promising treatment option for localized prostate cancer (PCa), offering oncologic control with reduced adverse effects compared to radical therapies. Various energy modalities, such as high-intensity focused ultrasound, cryotherapy, irreversible electroporation, and focal laser ablation, among others, selectively target malignant prostate tissue while sparing surrounding structures. Advances in imaging techniques, particularly multiparametric magnetic resonance imaging and prostate-specific membrane antigen-positron emission tomography/computed tomography, have improved lesion localization, patient selection, and treatment monitoring. The incorporation of artificial intelligence is enhancing tumor detection and predicting treatment outcomes. Although significant advancements have been made, challenges such as the lack of long-term data, treatment protocol standardization, and regulatory hurdles still limit widespread adoption. This review explores the current state of focal therapy for prostate cancer, highlighting its mechanisms, technological innovations, clinical outcomes, and future directions.

Indexed as

Ablative energiesFocal therapyFusion biopsyMultiparametric imagingProstate cancer

Identifiers

PMID41908235
PMCPMC13030951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.